Direct Meds review
Everything is sold by the quarter and quoted by the day. One of the daily figures is the other molecule's.
The verdict
Direct Meds contradicts itself in public. Its tirzepatide page carries two daily rates. Only one agrees with the price beside it. The other is the semaglutide figure, transplanted. Every headline is hedged 'as low as' on top of that.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Injection
- From $297/mo
- Oral
- From $249/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- Not published by the provider
Direct Meds runs a portal rather than a storefront. Both molecules appear in both routes. Every line is sold as a multi-month supply. The pages state which: twelve weeks for the injections, thirteen for the tablets.
Who writes the prescription, and what do they see?
The prescription is arranged through the portal. A clinician reviews an intake before dispensing. The pages state flow codes and supply lengths rather than describing the clinician. What the intake asks is not published.
No line is sold by the calendar month, though every figure is presented as one. What is bought is a supply block. The pages disclose its length beside a flow code rather than in the price. The daily framing shrinks the number a reader sees. It also conceals what is owed at purchase.
What happens when the dose goes up?
No line says what its figure does at a higher dose. One oral tier runs against the category's habit. Certain dosages fall below the advertised number rather than above it. That makes the headline a ceiling. Unusual, and disclosed rather than discovered.
What the price includes
Check the daily figures before trusting any of them. Only one of the two on the tirzepatide page reconciles with that page's own price; the other reproduces the semaglutide arithmetic. A pricing page carrying an error about its own product is a reason to confirm every number on it directly.
What it claims, and what it cites
Each line is compounded. Nothing here is FDA-approved, and no agency examines it before it ships. No pharmacy is named.
Where it holds up, and where it does not
- Strength: Supply length appears beside every figure
- Strength: Flow codes are visible in the portal
- Strength: One oral tier undercuts its own headline
- Limitation: One published daily rate contradicts its own price
- Limitation: The quoted unit is not the billed unit
- Limitation: Every figure carries an unexplained hedge
- Limitation: Nothing describes a higher dose
What the evidence says about this kind of treatment
The assessment above is about Direct Meds. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who will verify each number against the portal before ordering.
- Wrong for
- A reader who wants to buy a single month of anything.
The evidence behind what Direct Meds prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Direct Meds compares
| Seller | Who it suits | Go |
|---|---|---|
 GobyMeds | A reader who wants a monthly price that holds at any dose, with a cheaper starter bundle as the alternative | See GobyMeds → |
 June Health | A reader who wants the cost of escalating known at enrollment, not at month three | See June Health → |
 NuBloom | Readers who want the top dose priced before starting the lowest | See NuBloom → |
More GLP-1 telehealth sellers reviews: 1st Optimal24hrDOCAbundRXActinAgelessRxAHBARx
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Which daily figure is correct for tirzepatide?
- The higher of the two. It reconciles with that page's own price; the lower one reproduces the semaglutide arithmetic.
- Is a month available?
- No line is sold by the calendar month. Each is a multi-month supply block, and the pages state the length beside a flow code.
- Why does the oral price below its headline?
- Certain dosages fall below the advertised number rather than above it, which makes that headline a ceiling on the line.
- Is Direct Meds expensive compared with other GLP-1 telehealth sellers?
- Direct Meds publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Direct Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.